Table 3. Influence of vascular access in patients undergoing haemodialysis.
| Types of vascular access |
|||||||||
|---|---|---|---|---|---|---|---|---|---|
| AVF | p | AVG | p | CAT | p | ||||
| Vascular access % (n) | 53 | (17) | 19 | (6) | 28 | (9) | n.s. | ||
| endotoxin [EU/ml] | 7.4 | (0.0, 13.6) | 8.9 | (0.0, 15.2) | 10.8 | (3.5, 27.8) | n.s. | ||
| sCD14 [μg/ml] | 3.4 | (2.5, 4.9) | 2.9 | (2.5, 3.6) | 3.6 | (2,8, 4.2) | n.s. | ||
| LBP [μg/ml] | 28.2 | (21.1, 52.4) | 45.5 | (20.4, 65.4) | 26.6 | (23.3, 36.1) | n.s. | ||
| DAO [ng/ml] | 28.8 | (19.4, 38.1) | 26.3 | (24.2, 47.0) | 36.9 | (26.9, 55.0) | n.s. | ||
| phagocytosis [% change to healthy controls] | 61.6 | (46.9, 92.7) | 87.2 | (72.7, 111.9) | 87.2 | (72.7, 111.9) | n.s. | ||
| TNFα [pg/ml] | 0.7 | (0.0, 5.4) | 3.6 | (0.4, 13.5) | § | 0.0 | (0.0, 0.0) | ||
| sIL6R [ng/ml] | 225 | (175, 263) | 162 | (150, 238) | § | 350 | (193, 413) | ||
| sTNFR1 [ng/ml] | 28.0 | (22.6, 31.7) | 21.6 | (13.5, 29.3) | § | 44.1 | (33.0, 45.6) | ||
| CRP [mg/l] | 1.6 | (0.6, 9.7) | § | 8.0 | (1.3, 25.2) | 9.5 | (8.1, 36.0) | ||
| Mortality % (n) | |||||||||
| All causes | 34 | (4) | 33 | (2) | 67 | (6) | n.s. | ||
| Infections | 24 | (4) | 33 | (2) | 22 | (2) | n.s. | ||
§Significant difference to patients with catheter, n.s. not significant, Median (Q1, Q3) unless stated otherwise.
AVF arteriovenous fistula, AVG arteriovenous graft, CAT catheter, sCD14 soluble CD14, LBP LPS binding protein, DAO diamine-oxidase, sIL6R soluble interleukin 6 receptor, sTNFR1 soluble TNF receptor 1.